TCIM
AQST icon

TIAA CREF Investment Management’s Aquestive Therapeutics AQST Stock Holding History

TIAA CREF Investment Management’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$150K Hold
21,725
– – ﹤0.01% 2920
2018
Q4 		$137K Buy
+21,725
New +$274K ﹤0.01% 2932

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TIAA CREF Investment Management's AQST Position: Q1 2019 in Review

TIAA CREF Investment Management held its Aquestive Therapeutics (AQST) position steady in Q1 2019 at 21,725 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #2920.

TIAA CREF Investment Management first reported a position in AQST in Q4 2018 and has held it in 2 quarters since. 49 funds tracked by Wall St. Rank hold AQST as of Q1 2019.

  • TIAA CREF Investment Management held 21,725 shares of Aquestive Therapeutics worth $150K as of Q1 2019.
  • TIAA CREF Investment Management left its Aquestive Therapeutics share count unchanged in Q1 2019.
  • Aquestive Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2920 holding.
  • TIAA CREF Investment Management first reported a position in Aquestive Therapeutics in Q4 2018 and has held it in 2 quarters since.
  • 49 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.